Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorFinance
Phone212-590-9070
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.15 million
Profitability
Miscellaneous
Employees148
OptionableOptionable
Cronos Group (NASDAQ:CRON) Frequently Asked Questions
What is Cronos Group's stock symbol?
Cronos Group trades on the NASDAQ under the ticker symbol "CRON."
When is Cronos Group's next earnings date?
What price target have analysts set for CRON?
4 analysts have issued 1-year price targets for Cronos Group's shares. Their predictions range from $9.00 to $9.00. On average, they anticipate Cronos Group's share price to reach $9.00 in the next twelve months. This suggests that the stock has a possible downside of 57.7%. View Analyst Price Targets for Cronos Group.
What is the consensus analysts' recommendation for Cronos Group?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cronos Group.
Has Cronos Group been receiving favorable news coverage?
Headlines about CRON stock have been trending neutral on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cronos Group earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
Are investors shorting Cronos Group?
Cronos Group saw a increase in short interest in January. As of January 31st, there was short interest totalling 23,266,759 shares, an increase of 8.4% from the January 15th total of 21,461,058 shares. Based on an average trading volume of 20,538,925 shares, the days-to-cover ratio is currently 1.1 days. View Cronos Group's Current Options Chain.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include Canopy Growth (CGC), Tilray (TLRY), Aurora Cannabis (ACB), STADA Arzneimittel (STDAF), USANA Health Sciences (USNA), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), Canopy Rivers (RIV), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), China Jo-Jo Drugstores (CJJD), Mannatech (MTEX), GLG Life Tech (GLGLF) and Cyanotech (CYAN).
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 32)
- Mr. William Hilson, Chief Financial Officer
- Mr. David Hsu, Chief Operating Officer
- Ms. Xiuming Shum, Gen. Counsel & Corp. Sec.
- Mr. Jeffrey Jacobson, VP of Bus. Devel.
Who are Cronos Group's major shareholders?
Cronos Group's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Chescapmanager LLC (5.04%), ETF Managers Group LLC (3.90%), JW Asset Management LLC (0.61%), TD Asset Management Inc. (0.31%), Two Sigma Advisers LP (0.22%) and Gerber Kawasaki Wealth & Investment Management (0.12%).
Which institutional investors are selling Cronos Group stock?
CRON stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., Bank of America Corp DE, Sigma Planning Corp, JW Asset Management LLC, Chescapmanager LLC, Creative Planning, IFP Advisors Inc and Benjamin F. Edwards & Company Inc..
Which institutional investors are buying Cronos Group stock?
CRON stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, TD Asset Management Inc., Two Sigma Advisers LP, Millennium Management LLC, Two Sigma Investments LP, CIBC Asset Management Inc, Toronto Dominion Bank and Virtu Financial LLC.
How do I buy shares of Cronos Group?
Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cronos Group's stock price today?
One share of CRON stock can currently be purchased for approximately $21.29.
How big of a company is Cronos Group?
Cronos Group has a market capitalization of $3.80 billion and generates $3.15 million in revenue each year. The company earns $1.92 million in net income (profit) each year or $0.01 on an earnings per share basis. Cronos Group employs 148 workers across the globe.
What is Cronos Group's official website?
How can I contact Cronos Group?
Cronos Group's mailing address is 720 KING STREET W SUITE 320, TORONTO A6, M5V 2T3. The company can be reached via phone at 212-590-9070.
MarketBeat Community Rating for Cronos Group (NASDAQ CRON)
MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe CRON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.
